Medical management of langerhans cell histiocytosis from diagnosis to treatment

Author： Donadieu Jean   Chalard François   Jeziorski Eric  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.9, 2012-06, pp. : 1309-1322

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug therapy for the treatment of Langerhans cell histiocytosis

By McClain Kenneth L  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 14, 2005-11 ,pp. : 2435-2441

Informa Healthcare

Access to resources Recommend Favorite

Multisystem Langerhans Cell Histiocytosis in Children: Current Treatment and Future Directions

By Minkov Milen  

Pediatric Drugs, Vol. 13, Iss. 2, 2011-04 ,pp. : 75-86

Adis International

Access to resources Recommend Favorite

Clonal Status and Clinicopathological Features of Langerhans Cell Histiocytosis

By Gong L   Zhang W-D   Li Y-H   Liu X-Y   Yao L   Han X-J   Zhu S-J   Lan M   Zhang W  

The Journal of International Medical Research, Vol. 38, Iss. 3, 2010-06 ,pp. : 1099-1105

Field House Publishing

Access to resources Recommend Favorite

Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure

By Minkov Milen  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 12, 2012-08 ,pp. : 1671-1673

Informa Healthcare

Access to resources Recommend Favorite

The use of BRAF V600E mutation‐specific immunohistochemistry in pediatric Langerhans cell histiocytosis

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 307-315

John Wiley & Sons Inc

Access to resources Recommend Favorite